Enfuvirtide, a new treatment for HIV infection
Canadian Coordinating Office for Health Technology Assessment

Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation
Canadian Coordinating Office for Health Technology Assessment. Enfuvirtide, a new treatment for HIV infection. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2003

Authors' objectives
To summarize the available information on the use of enfuvirtide - also called pentafuside or T-20 - (sold as Fuzeon(TM), manufactured by Hoffmann-La Roche), for the treatment of patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.

Authors' conclusions
The addition of enfuvirtide to a failing antiretroviral regimen sustains the clinical response over one year. Long-term efficacy and safety studies are needed to determine this drug's place in therapy. The current recommendation is to limit its use to heavily treatment-experienced patients. An open-label phase III study is underway to assess serious adverse events.

Project page URL
https://www.ccohta.ca

Indexing Status
Subject indexing assigned by CRD

MeSH
Anti-HIV Agents /therapeutic use; Costs and Cost Analysis; HIV Fusion Inhibitors /therapeutic use; HIV Infections /drug therapy; Peptide Fragments /therapeutic use

Language Published
English, French

Country of organisation
Canada

Address for correspondence
600-865 Carling Avenue, Ottawa, ON K1S 5S8, Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392; Email: jills@ccohta.ca

AccessionNumber
32003000843

Date bibliographic record published
25/09/2003

Date abstract record published
25/09/2003